Академический Документы
Профессиональный Документы
Культура Документы
Am J Clin Nutr 2013;97:4557. Printed in USA. 2013 American Society for Nutrition
45
46
VAN DER
MERWE ET AL
Subjects
The study was carried out in the West Kiang region of The
Gambia from May 2007 to October 2008. The Gambian climate
is tropical with 2 main seasons that consist of a hot, rainy season
(June to October) and a cooler, dry season (November to May).
West Kiang is 145 km inland from the capital and spans an area of
80 km2. Keneba is the largest village in this rural area, where
subsistence farming (primarily rice and groundnuts) predominates.
A combination of in utero growth retardation, poor-quality and
frequently contaminated weaning foods, and high levels of infection cause moderately severe growth faltering in almost all
children with an onset at w3 mo postpartum. All infants aged 3
mo who were living in the 16 largest villages of West Kiang and
not enrolled in any other study were eligible to take part in the
current study. In total, 220 infants were assessed for eligibility, of
whom 183 infants were randomly assigned (Figure 1). Infants
with severe congenital abnormalities that could affect growth and
development, infants from multiple births, and infants with known
HIV infection were ineligible for participation.
Potential subjects were identified from the West Kiang Demographic Surveillance System (http://www.ing.mrc.ac.uk/research_
areas/west_kiang_dss.aspx). Subjects were automatically allocated
a study number by the database system on recruitment. Each study
number had previously been randomly assigned to one of 4
treatment codes (4 rather than 2 codes were used to promote
47
FIGURE 1. Subject flowchart summarized according to Consolidated Standards of Reporting Trials that shows the number of subjects randomly assigned,
lost to follow-up, and analyzed by treatment arm.
intestinal leakiness. Therefore, intestinal permeability is measured as the urinary lactulose concentration divided by the urinary mannitol concentration. In addition, the ratio of urinary
lactulose:lactose is measured as an indication of lactase activity.
By measuring the total urine volume passed over 5 h postdose
(Hollister U-bag; Abbot Laboratories), the percentage of recoveries of the 2 probes was calculated as a reflection of the
amounts taken up by the passive and paracellular intestinal
routes. Urine samples were stored with 23 drops of chlorhexidinegluconate (5% wt:vol) as a bacteriostatic agent.
Cognitive development at 12 mo
At 12 mo of age (67 d), infants were brought in to the MRC
Keneba field station for their final follow-up visit, during which
cognitive development was tested by using a 2-step means-end
problem-solving test (Willatts Infant Planning Test) (4042)
and a single-object task attention assessment (toddler attention
assessment) (43). The 12-mo time point for assessments was
determined in a pilot study that evaluated the frequency distribution of test scores in 75 West Kiang infants aged 1012 mo.
On the morning of the test, mothers were asked to ensure that
their infant had been fed before the 15-min test. For standardization, the 2-step Infant Planning Test was performed first and
was followed by the single-object task toddler assessment. If an
infant did not respond during the Infant Planning Test, the attention assessment was completed first, and a second attempt at
the planning test was made thereafter. The assessment was completed in a restricted-access room with few distractions. For both
tests, the mother was asked to sit on a chair with her infant on her
lap facing a table placed in front of her. She was asked not to help,
encourage, or prompt her child by either words or actions and not to
48
VAN DER
MERWE ET AL
49
between study groups separately. For other FAs and combinations, we used absolute concentrations. Sex differences between
cognitive development test scores were assessed by using regression analysis. For the assessment of test validity, correlations between scores of a second observer who scored a sample
of the Infant Planning Test and those of the first observer were
examined by using Pearsons product-moment correlation coefficients. Bias-corrected 95% CIs for correlation coefficients
were estimated by using the bootstrap approach. The bias between markers was tested by using a paired t test.
RESULTS
TABLE 1
Baseline characteristics of study participants1
Characteristics
Fish-oil group
Control group
Differences2
49 (56)
92.3 6 4.255
68
50 (59)
93.2 6 4.22
68
233
20.10
26
28
4
19
26
4
7
2
0
4
6
87
5.86 6 0.84
60.1 6 2.20
40.1 6 1.24
13.2 6 1.15
16.1 6 0.75
6.84 6 1.24
8.84 6 1.62
8.24 6 1.50
(n = 85)
70.2 6 23.8
23.0 (14.5, 35.5)6
125 6 42.5
9
10
85
5.75 6 0.83
60.0 6 25.6
40.0 6 1.29
13.0 6 1.12
16.0 6 0.90
6.72 6 1.38
8.60 6 1.71
8.21 6 1.79
(n = 83)
76.4 6 23.2
24.3 (16.1, 40.4)
133 6 39.9
25
24
0.11
0.10
0.10
0.22
0.10
0.12
0.24
0.03
3.75 6 0.89
1.15 (0.81, 1.66)
6.66 6 1.41
80
33.0 6 3.01
0.95 (0.77, 0.11)
3.02 (2.23, 5.31)
85
0.15 (0.10, 0.22)
0.75 (0.53, 1.10)
0.26 (0.19, 0.45)
7.02 6 3.46
82
1029 (627, 1534)
4.00 6 0.95
1.31 (0.82, 2.03)
6.90 6 1.51
78
33.0 6 2.61
0.88 (0.69, 0.12)
2.91 (2.22, 4.67)
82
0.15 (0.12, 0.20)
0.72 (0.50, 0.98)
0.24 (0.16, 0.34)
6.21 6 2.94
83
1058 (610, 1639)
20.25
20.16
20.24
0.00
0.07
0.11
0.00
0.03
0.02
0.81
229
26.20
21.30
28.00
1
AA, arachidonic acid; FA, fatty acid; HC, head circumference; LMR, lactulose-mannitol ratio; MUAC, midupper arm
circumference.
2
Fish-oil group mean or median minus control group mean or median.
3
Percentage.
4
Age on the first day of supplementation.
5
Mean 6 SD (all such values).
6
Median; 25th, 75th percentiles in parentheses (all such values).
50
VAN DER
MERWE ET AL
available for 172 infants (87 infants in the fish-oil group and 85
infants in the control group) from which growth and other
outcomes could be analyzed (Figure 1). Baseline characteristics
of infants were distributed evenly with no large differences
observed between study groups (Table 1). Compliance rates
$90% were measured for 85% of infants (74 of 87 infants) in
the fish-oil group and 88% of infants (75 of 85 infants) in the
control group. The remaining 23 infants all showed compliance
rates .75%. Of infants treated, 155 infants (90%) came for their
outcome measurements at 12 mo of age. Eight infants from the
fish-oil group and 9 infants from the control group were lost to
follow-up because they moved away from the area.
Effect of supplementation on PUFA status
Fish-oil supplementation resulted in a significant increase in
the percentage of DHA and EPA in plasma total lipids, which
confirmed the tissue uptake of n23 LC-PUFAs in fish-oilsupplemented infants (Table 2). Arachidonic acid (AA) and total
n26 FA concentrations did not differ significantly between fishoil and control groups. See Table 1 under Supplemental data
in the online issue for other FAs measured.
When compliance and the number of doses received were fitted to
the regression model, we observed similar results with some evi-
TABLE 2
Plasma fatty acid endpoints by treatment groups1
Endpoint
Main LC-PUFAs (percentage of total FA)
DHA
EPA
AA
Main LC-PUFAs (ng/mL)
DHA
EPA
AA
Other FAs and FA indicators (ng/mL)
Saturated (8:018:0)6
Saturated (20:024:0)7
Monounsaturated8
18:3n23
22:5n23
18:2n26c
20:3n26
Total n23 FAs (ng/mL)
Total n26 FAs (ng/mL)
22:5n26
Essential and nonessential PUFAs9
DHA:22:5n26 ratio
AA:EPA + DHA ratio
1
2
Fish-oil group
(n = 86)
Control group
(n = 83)
Effect size
(95% CI)2
P2
4.87 6 1.013
2.13 [1.66, 2.95]4
7.28 6 1.52
4.44 6 0.81
1.34 [0.94, 1.72]
7.25 6 1.35
,0.001
,0.001
0.680
70.0 6 20.6
31.1 [22.8, 43.7]
104 6 29.0
65.4 6 16.3
19.3 [14.3, 25.0]
107 6 27.6
0.051
,0.001
0.578
516 6 150
11.6 6 2.79
350 6 99.7
4.86 6 2.87
13.2 6 4.64
317 6 93.8
17.1 6 5.80
123; 41
440; 118
2.59 6 1.00
1.88 6 0.39
28.4 6 7.34
1.05 6 0.26
541 6 137
11.8 6 3.60
373 6 106
4.76 6 2.16
11.9 6 3.82
322 6 91.9
19.1 6 6.49
104; 28
452; 119
3.32 6 1.24
1.75 6 0.34
21.5 6 7.31
1.28 6 0.31
0.224
0.739
0.139
0.893
0.051
0.761
0.039
,0.001
0.595
,0.001
0.018
,0.001
,0.001
for.
Mean 6 SD (all such values).
Median; 25th, 75th percentiles in brackets (all such values)
5
Because data were log transformed, effect sizes and CIs are expressed as the antilog of calculated CIs and regression
coefficients, which indicate the ratio of the geometric mean of fish-oil to control groups.
6
Includes 18:0, 17:0, 16:0, 15:0, 14:0, 13:0, 12:0, 11:0, 10:0, and 8:0.
7
Includes 24:0, 23:0, 22:0, 21:0, and 20:0.
8
Includes 14:1, 15:1, 16:1, 17:1, 18:1n9c, 20:1, 22:1n29, and 24:1.
9
Ratio of n26 + n23 to n29 unsaturated PUFAs. Ordinarily, n27 PUFAs should be included in the ratio as nonessential FAs, but data for these were unavailable.
3
4
51
Gut permeability
Cognitive development at 12 mo
52
VAN DER
MERWE ET AL
TABLE 3
Effect of n23 LC-PUFA supplementation on primary endpoints at 9 mo by treatment group1
Fish-oil group
(n = 87)
Endpoints
Control group
(n = 85)
Effect size
(95% CI)
2,3
20.90
20.57
20.79
20.52
20.27
20.60
20.01
0.41
6 1.094
6 0.99
6 1.02
6 0.84
6 0.92
6 0.99
6 0.85
6 1.12
86
4.22 6 2.48
0.22 [0.14, 0.37]7
0.50 [0.30, 0.91]
0.21 [0.11, 0.38]
21.20
20.76
21.07
20.64
20.66
20.79
20.30
0.27
6 1.28
6 1.10
6 1.30
6 1.06
6 1.18
6 1.12
6 1.09
6 1.29
81
4.51 6 2.04
0.22 [0.15, 0.29]
0.64 [0.42, 0.98]
0.23 [0.15, 0.32]
0.15
0.12
0.79
20.01
0.31
0.08
0.27
0.16
20.34
0.96
0.79
0.91
(20.08, 0.38)
(20.14, 0.38)
(20.27, 0.90)
(20.18, 0.17)
(0.06, 0.56)
(20.16, 0.33)
(0.00, 0.55)
(20.16, 0.48)
(21.04; 0.35)
(0.87, 1.07)8
(0.60, 1.05)8
(0.72, 1.15)8
0.208
0.377
0.084
0.954
0.017
0.503
0.048
0.326
0.332
0.507
0.110
0.434
1
HC, head circumference; LC-PUFA, long-chain PUFA; LMR, lactulose:mannitol ratio; MUAC, midupper arm
circumference.
2
General least-squares regression analysis with the dependent variable and treatment entered and baseline controlled
for. Median growth measurements of each individual were used.
3
With the use of WHO reference curves (38, 39).
4
Mean 6 SD (all such values).
5
Data were log transformed.
6
Regression analysis fitting (log)lactulose on (log)mannitol with baseline values controlled for.
7
Median; 25th, 75th percentiles in brackets (all such values).
8
For log-transformed data, effect sizes and CIs are expressed as the antilog of calculated CIs and regression coefficients, which indicate the ratio of geometric means of fish-oil to control groups.
9
Regression analysis fitting (log)lactulose on (log)lactose with baseline values controlled for.
TABLE 4
Anthropometric indexes at 12 mo of age by treatment group with baseline measures controlled for1
Fish-oil group
(n = 79)
Endpoint
Control group
(n = 76)
Effect size
(95% CI)2
Anthropometric z scores
Weight-for-age
Weight-for-length
Length-for-age
HC-for-age
MUAC-for-age
BMI-for-age
Triceps skinfold thicknessfor-age
Subscapular skinfold thicknessfor-age
1
21.09
20.79
-0.1.00
20.61
20.20
20.69
0.19
0.23
6
6
6
6
6
6
6
6
1.134
1.10
1.11
0.87
0.94
1.12
0.79
1.05
21.41
21.03
21.30
20.72
20.64
20.90
20.15
20.14
6
6
6
6
6
6
6
6
1.21
0.97
1.32
1.02
0.98
0.94
0.82
1.02
0.11
0.17
0.08
20.04
0.33
0.09
0.31
0.36
(20.13, 0.35)
(20.09, 0.43)
(20.15, 0.32)
(20.24, 0.16)
(0.09, 0.57)
(20.15, 0.34)
(0.06, 0.55)
(0.06, 0.67)
0.357
0.207
0.489
0.713
0.008
0.459
0.014
0.019
53
Endpoint
Acute-phase proteins (n)
Plasma albumin (mg/L)
AGP (g/L)
CRP (mg/L)
Intestinal inflammation (n)
Calprotectin dry weight (mg/kg)
Calprotectin wet weight (mg/kg)
Concentrations out of normal range
Plasma albumin6
AGP6
CRP6
Calprotectin9
86
35.3 6 3.12
1.01 [0.85, 1.34]4
4.7 [3.1, 8.2]
76
78.0 [43, 120]
647 [357, 996]
5/86
44/86
39/86
70/79
[0.77,
[40.4,
[34.6,
[81.4,
10.9]7
61.9]
56.1]
95.8]
Control
group
83
35.3 6 2.8
1.03 [0.82, 1.36]
4.7 [3.2, 7.9]
69
66.5 [46, 138]
552 [382, 1145]
3/83
43/83
36/83
62/74
Effect size
(95% CI)
0.8803
0.5963
0.8383
0.4273
0.9338
0.5018
0.7968
0.3868
[20.49, 7.71]
[40.8, 62.8]
[32.5, 54.3]
[75.2, 92.4]
for.
4
Associated covariates
Maternal schooling
Weaning
DISCUSSION
TABLE 6
Morbidity endpoints by treatment group
Morbidity rates
Unwell, any complaint2
Diarrhea4
Fever4
Respiratory complaints4
Nurse or doctor visits4
Vomiting4
Abnormal bleeds/other complaints4,5
Fish-oil group
(n = 87)
Control group
(n = 85)
36033
474
1479
1645
186
251
12
3088
605
1297
1503
161
268
17
Effect size
(95% CI)1
0.13
20.27
0.11
0.06
0.13
20.12
(20.08, 0.34)
(20.61, 0.06)
(20.12, 0.34)
(20.2, 0.32)
(20.10, 0.36)
(20.56, 0.03)
P1
0.238
0.110
0.338
0.670
0.268
0.570
1
Negative binomial regression by using the number of visits an infant was reported ill or with a symptom as a negative
binomial variable with log(number of visits) controlled for.
2
Number of visits at which one or more symptoms were recorded.
3
Total recorded (all such values).
4
Number of visits at which any infant was reported to have had this complaint.
5
Too few observations to make a meaningful statistical comparison.
54
VAN DER
MERWE ET AL
TABLE 7
Cognitive development endpoints by treatment group1
Endpoint
2-step Infant Planning Test (n)
Average total intention score
Average intentional solutions
Toddler attention assessment (n)
Inattention rate
Mean look duration
Fish-oil
group
Control
group
Effect size
(95% CI)
73
4.63 6 3.772
0.44 6 0.52
74
2.38 [1.70, 2.91]4
23.8 [19.5, 33.9]
65
4.45 6 3.71
0.43 6 0.54
69
2.37 [1.70, 2.91]
23.2 [17.2, 35,5]
0.7593
0.8713
0.8683
0.8843
1
Assessments could not be made for the Infant Planning Test in 17 cases (6 cases in the fish-oil group and 11 cases in
the control group) and for the attention test in 12 cases (5 cases in the fish-oil group and 7 cases in the control group)
because the children were disturbed or crying or the video recording malfunctioned.
2
Mean 6 SD (all such values).
3
General least-squares regression analysis with the dependent variable and treatment entered.
4
Median; 25th, 75th percentiles in brackets (all such values).
5
Because data were log transformed, effect sizes and CIs are expressed as the antilog of calculated CIs and regression
coefficients, which indicate the ratio of the geometric mean of fish-oil to control groups.
55
REFERENCES
1. Haghighi P, Wolf PL. Tropical sprue and subclinical enteropathy:
a vision for the nineties. Crit Rev Clin Lab Sci 1997;34:31341.
2. Fagundes-Neto U, Viaro T, Wehba J, Patricio FR, Machado NL.
Tropical enteropathy (environmental enteropathy) in early childhood:
a syndrome caused by contaminated environment. J Trop Pediatr 1984;
30:2049.
3. Lunn PG, Northrop-Clewes CA, Downes RM. Intestinal permeability,
mucosal injury, and growth faltering in Gambian infants. Lancet 1991;
338:90710.
4. Lunn PG, Northrop-Clewes CA, Downes RM. Recent developments in
the nutritional management of diarrhoea. 2. Chronic diarrhoea and
malnutrition in The Gambia: studies on intestinal permeability. Trans R
Soc Trop Med Hyg 1991;85:811.
5. Thomas G, Clain DJ, Wicks AC. Tropical enteropathy in Rhodesia. Gut
1976;17:88894.
6. Goto K, Chew F, Torun B, Peerson JM, Brown KH. Epidemiology of
altered intestinal permeability to lactulose and mannitol in Guatemalan
infants. J Pediatr Gastroenterol Nutr 1999;28:28290.
7. Goto R, Panter-Brick C, Northrop-Clewes CA, Manahdhar R, Tuladhar
NR. Poor intestinal permeability in mildly stunted Nepali children:
associations with weaning practices and Giardia lamblia infection. Br J
Nutr 2002;88:1419.
8. McKay S, Gaudier E, Campbell DI, Prentice AM, Albers R. Environmental enteropathy: new targets for nutritional interventions. Int
Health 2010;2:17280.
56
VAN DER
MERWE ET AL
9. Lunn PG. The impact of infection and nutrition on gut function and
growth in childhood. Proc Nutr Soc 2000;59:14754.
10. Menzies IS, Zuckerman MJ, Nukajam WS, Somasundaram SG, Murphy B, Jenkins AP, Crane RS, Gregory GG. Geography of intestinal
permeability and absorption. Gut 1999;44:4839.
11. Northrop-Clewes CA, Lunn PG, Downes RM. Lactose maldigestion in
breast-feeding Gambian infants. J Pediatr Gastroenterol Nutr 1997;24:
25763.
12. Behrens RH, Lunn PG, Northrop CA, Hanlon PW, Neale G. Factors
affecting the integrity of the intestinal mucosa of Gambian children.
Am J Clin Nutr 1987;45:143341.
13. Labenthal E. Prolonged small intestinal mucosal injury as a primary
cause of intractable diarrhoea of infancy. In: Labenthal E, ed. Chronic
diarrhea in children. New York, NY: Raven Press, 1986:529.
14. Teitelbaum JE, Allan Walker W. Review: the role of omega 3 fatty
acids in intestinal inflammation. J Nutr Biochem 2001;12:2132.
15. Belluzzi A. n23 Fatty acids for the treatment of inflammatory bowel
diseases. Proc Nutr Soc 2002;61:3915.
16. Belluzzi A, Boschi S, Brignola C, Munarini A, Cariani G, Miglio F.
Polyunsaturated fatty acids and inflammatory bowel disease. Am J Clin
Nutr 2000;71:339S42S.
17. Calder PC. Dietary modification of inflammation with lipids. Proc Nutr
Soc 2002;61:34558.
18. Calder PC. Polyunsaturated fatty acids and inflammation. Prostaglandins Leukot Essent Fatty Acids 2006;75:197202.
19. Calder PC. Polyunsaturated fatty acids, inflammatory processes and
inflammatory bowel diseases. Mol Nutr Food Res 2008;52:88597.
20. Simmer K. Long-chain polyunsaturated fatty acid supplementation in
infants born at term. Cochrane Database Syst Rev 2001;CD000376.
21. Simmer K, Patole SK, Rao SC. Long-chain polyunsaturated fatty acid
supplementation in infants born at term. Cochrane Database Syst Rev
2008;CD000376.
22. Simmer K, Schulzke SM, Patole S. Long-chain polyunsaturated fatty
acid supplementation in preterm infants. Cochrane Database Syst Rev
2008;CD000375.
23. Makrides M, Collins CT, Gibson RA. Impact of fatty acid status on
growth and neurobehavioural development in humans. Matern Child
Nutr 2011;7(suppl 2):808.
24. Brown JL, Pollitt E. Malnutrition, poverty and intellectual development. Sci Am 1996;274:3843.
25. Whaley SE, Sigman M, Espinosa MP, Neumann CG. Infant predictors
of cognitive development in an undernourished Kenyan population. J
Dev Behav Pediatr 1998;19:16977.
26. Neumann C, McDonald MA, Sigman M, Bwibo N, Marquardt M.
Relationships between morbidity and development in mildly to moderately malnourished Kenyan toddlers. Pediatrics 1991;88:93442.
27. Grantham-McGregor SM, Fernald LC, Sethuraman K. Effects of health
and nutrition on cognitive and behavioural development in children in
the first three years of life. Part 2: infections and micronutrient deficiencies: iodine, iron, and zinc. Food Nutr Bull 2000;21:7699.
28. Mendez MA, Adair LS. Severity and timing of stunting in the first two
years of life affect performance on cognitive tests in late childhood.
J Nutr 1999;129:155562.
29. Powell CA, Walker SP, Himes JH, Fletcher PD, Grantham-McGregor
SM. Relationships between physical growth, mental development and
nutritional supplementation in stunted children: the Jamaican study.
Acta Paediatr 1995;84:229.
30. Makrides M, Neumann MA, Gibson RA. Is dietary docosahexaenoic
acid essential for term infants? Lipids 1996;31:1159.
31. Birch EE, Hoffman DR, Uauy R, Birch DG, Prestidge C. Visual acuity
and the essentiality of docosahexaenoic acid and arachidonic acid in
the diet of term infants. Pediatr Res 1998;44:2019.
32. Birch EE, Garfield S, Hoffman DR, Uauy R, Birch DG. A randomized
controlled trial of early dietary supply of long-chain polyunsaturated
fatty acids and mental development in term infants. Dev Med Child
Neurol 2000;42:17481.
33. Forsyth JS, Willatts P, DiModogno MK, Varma S, Colvin M. Do longchain polyunsaturated fatty acids influence infant cognitive behaviour?
Biochem Soc Trans 1998;26:2527.
34. Helland IB, Saugstad OD, Smith L, Saarem K, Solvoll K, Ganes T, Drevon
CA. Similar effects on infants of n23 and n26 fatty acids supplementation
to pregnant and lactating women. Pediatrics 2001;108:E82.
35. Helland IB, Smith L, Saarem K, Saugstad OD, Drevon CA. Maternal
supplementation with very-long-chain n23 fatty acids during preg-
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
a formula enriched with a low eicosapentanoic acid fish oil for 4 months.
Eur J Pediatr 2000;159:4953.
Lapillonne A, Carlson SE. Polyunsaturated fatty acids and infant
growth. Lipids 2001;36:90111.
Lapillonne A, Clarke SD, Heird WC. Polyunsaturated fatty acids and
gene expression. Curr Opin Clin Nutr Metab Care 2004;7:1516.
Salem N Jr, Moriguchi T, Greiner RS, McBride K, Ahmad A, Catalan
JN, Slotnick B. Alterations in brain function after loss of docosahexaenoate due to dietary restriction of n23 fatty acids. J Mol Neurosci
2001;16:299307; discussion 31721.
Clements KM, Girard TA, Xing HC, Wainwright PE. Spontaneously
hypertensive and Wistar Kyoto rats differ in delayed matching-to-place
performance and response to dietary long-chain polyunsaturated fatty
acids. Dev Psychobiol 2003;43:5769.
Gamoh S, Hashimoto M, Hossain S, Masumura S. Chronic administration of docosahexaenoic acid improves the performance of radial arm
maze task in aged rats. Clin Exp Pharmacol Physiol 2001;28:26670.
Gamoh S, Hashimoto M, Sugioka K, Shahdat Hossain M, Hata N,
Misawa Y, Masumura S. Chronic administration of docosahexaenoic
acid improves reference memory-related learning ability in young rats.
Neuroscience 1999;93:23741.
Moriguchi T, Greiner RS, Salem N Jr. Behavioral deficits associated
with dietary induction of decreased brain docosahexaenoic acid concentration. J Neurochem 2000;75:256373.
Moriguchi T, Salem N Jr. Recovery of brain docosahexaenoate leads to
recovery of spatial task performance. J Neurochem 2003;87:297309.
Carlson SE, Werkman SH. A randomized trial of visual attention of
preterm infants fed docosahexaenoic acid until two months. Lipids
1996;31:8590.
Reisbick S, Neuringer M, Gohl E, Wald R, Anderson GJ. Visual attention in infant monkeys: effects of dietary fatty acids and age. Dev
Psychol 1997;33:38795.
Kupfermann I. Neurophysiology of learning. Annu Rev Psychol 1975;
26:36791.
Wiggins RC. Myelin development and nutritional insufficiency. Brain
Res 1982;257:15175.
57
71. Lauritzen L, Jorgensen MH, Olsen SF, Straarup EM, Michaelsen KF.
Maternal fish oil supplementation in lactation: effect on developmental
outcome in breast-fed infants. Reprod Nutr Dev 2005;45:53547.
72. Judge MP, Harel O, Lammi-Keefe CJ. Maternal consumption of a docosahexaenoic acid-containing functional food during pregnancy:
benefit for infant performance on problem-solving but not on recognition memory tasks at age 9 mo. Am J Clin Nutr 2007;85:15727.
73. Beaton GH, Ghassemi H. Supplementary feeding programs for young
children in developing countries. Am J Clin Nutr 1982;35:863916.
74. Hoare S, Poppitt SD, Prentice AM, Weaver LT. Dietary supplementation and rapid catch-up growth after acute diarrhoea in childhood. Br
J Nutr 1996;76:47990.
75. Sullivan PB, Mascie-Taylor CG, Lunn PG, Northrop-Clewes CA,
Neale G. The treatment of persistent diarrhoea and malnutrition: longterm effects of in-patient rehabilitation. Acta Paediatr Scand 1991;80:
102530.
76. Sullivan PB, Lunn PG, Northrop-Clewes C, Crowe PT, Marsh MN,
Neale G. Persistent diarrhea and malnutritionthe impact of treatment
on small bowel structure and permeability. J Pediatr Gastroenterol Nutr
1992;14:20815.
77. Schroeder DG, Brown KH. Nutritional status as a predictor of child
survival: summarizing the association and quantifying its global impact. Bull World Health Organ 1994;72:56979.
78. Dewey KG, Adu-Afarwuah S. Systematic review of the efficacy and
effectiveness of complementary feeding interventions in developing
countries. Matern Child Nutr 2008;4(suppl 1):2485.
79. Williams EA, Elia M, Lunn PG. A double-blind, placebo-controlled,
glutamine-supplementation trial in growth-faltering Gambian infants.
Am J Clin Nutr 2007;86:4217.
80. Darboe MK, Thurnham DI, Morgan G, Adegbola RA, Secka O, Solon
JA, Jackson SJ, Northrop-Clewes C, Fulford TJ, Doherty CP, et al.
Effectiveness of an early supplementation scheme of high-dose vitamin
A versus standard WHO protocol in Gambian mothers and infants:
a randomised controlled trial. Lancet 2007;369:208896.
81. Prentice AM, Paul AA. Fat and energy needs of children in developing
countries. Am J Clin Nutr 2000;72:1253S65S.